ClinicalTrials.gg
CompletedNCT00444912Updated Mar 13, 2014Results posted

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

A Phase 2 interventional study of G-CSF plus plerixafor and G-CSF plus plerixafor in Non-Hodgkin Lymphoma and Hodgkin Disease, sponsored by Genzyme, a Sanofi Company. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-03-13.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin — 1 open to participants now, 1 under way, none of them phase 3. Granulocyte Colony-Stimulating Factor · Lymphoma, Non-Hodgkin.

Enrollment
13th of 19
30 · median 36
Started
2006
the only one that year
Phase 2
15 of 19
1 open now
Registered
9th of 19
by date
Lead sponsor
8 of 19
Genzyme, a Sanofi Company

Among the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, this one is the 13th largest by enrollment, is the only one that started in 2006, is one of 15 in phase 2, and was the 9th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

1 of the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

Participants with non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD) will be assigned to one of 2 arms based on the immunophenotype of their lymphoma.

(A)Participants with CD20(-) lymphoma will undergo mobilization with granulocyte colony-stimulating factor (G-CSF) and plerixafor.

(B) Participants with CD20(+) lymphomas will undergo mobilization with rituximab, G-CSF, and plerixafor. They will receive a weekly dose of rituximab beginning 1 week prior to, and continuing until 2 weeks after, the first dose of G-CSF.

Participants in both groups will receive G-CSF twice daily for 4 days. In the evening on Day 4, a dose of plerixafor will be administered. Apheresis will be initiated the next morning. Participants will continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the next morning for up to a total of 4 aphereses or until ≥5*10\^6 CD34+ cells/kg are collected.

Participants who are transplanted will be monitored for the time to polymorphonuclear leukocytes (PMN), platelets (PLT), and lymphocyte engraftment. Follow-up assessments will be done at 100 days, and 6 and 12 months post-transplantation.

Read the detailed description

This is a single-center, 2-arm, non-randomized, open-label study to evaluate the safety of plerixafor when used in combination with rituximab (Rituxan®) and granulocyte colony-stimulating factor (G-CSF) in patients with relapsed or refractory Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL).

Participants will be assigned to one of 2 arms based on the immunophenotype of their lymphoma.

(A)Participants with CD20(-) lymphoma will undergo mobilization with G-CSF and plerixafor.

(B) Participants with CD20(+) lymphomas will undergo mobilization with rituximab, G-CSF, and plerixafor. They will receive a weekly dose of 375 mg/m2 rituximab by intravenous (iv) infusion beginning 1 week prior to, and continuing until 2 weeks after, the first dose of G-CSF.

Participants in both groups will receive 7.5 µg/kg G-CSF twice daily (morning and evening) for 4 days. In the evening (approximately 10:00 pm) on Day 4, a dose of plerixafor (240 µg/kg) will be administered. Apheresis will be initiated the next morning, approximately 10 to 11 hours after plerixafor is given. Participants will continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the next morning for up to a total of 4 aphereses or until ≥5*10\^6 CD34+ cells/kg are collected.

Participants with an adequate number of autologous peripheral blood stem cells (PBSCs) collected by apheresis will be admitted to the study center for the administration of high-dose chemotherapy and autologous transplantation. After transplantation, the times to PMN, PLT, and lymphocyte engraftment will be measured. Participants will remain hospitalized until they achieve an absolute granulocyte count of >500/µl in the peripheral blood. Graft durability will be assessed at 100 days, and 6 and 12 months post-transplantation.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

03

Conditions studied

  • Non-Hodgkin Lymphoma
  • Hodgkin Disease

Keywords

  • AMD3100
  • stem cell mobilization
  • autologous transplant
  • Non-Hodgkin Lymphoma
  • Hodgkin Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of diffuse large cell lymphoma, B-cell, T-cell or anaplastic histologies; peripheral T-cell lymphoma; small non-cleaved Burkitt-like lymphoma; or Hodgkin disease. NOTE: Participants diagnosed at a facility outside of Emory University will have their diagnosis confirmed by Emory University pathologists prior to being enrolled in this study.
  • Eligible for transplantation.
  • History of relapse of lymphoma following initial treatment with an anthracycline-containing regimen or disease that is or progresses during initial therapy with an anthracycline-containing regimen.
  • Immunophenotyping of the lymphoma at the time of diagnosis or relapse using flow cytometry or immunohistochemistry.
  • Presence of clinically- and/or radiologically-documented, measurable, and/or evaluable disease at the time of relapse.
  • Received 2 cycles of salvage chemotherapy.
  • Complete response (i.e., normal physical examination, lymph nodes, lymph node masses, and bone marrow) or a partial response (i.e., decrease of ≧50% in the size of lymph nodes or lymph node masses or decrease in size of liver/spleen on physical exam) to at least one cycle of a salvage chemotherapy regimen.
  • (ECOG) performance status of 0, 1, or 2.
  • Absolute granulocytes count ≧1.0*10\^9/l.
  • count ≧75*10\^9/l.
  • (AST) or alanine transaminase (ALT) ≦2.5 times the (ULN) or ≦5 times the ULN if liver involvement with lymphoma.
  • of at least 3 months.
  • >4 weeks since last cycle of chemotherapy.
  • Patient has recovered from all acute toxic effects of prior chemotherapy.
  • Signed .

Exclusion criteria

Exclusion Criteria (abbreviated list):

  • A second active (other than basal cell carcinoma of the skin).
  • Uncontrolled central nervous system involvement by lymphoma.
  • Positive/history of retroviral infection (, HTLV-1).
  • Active infection requiring antibiotics during planned lymphoma-related therapy.
  • Previous treatment with high-dose chemotherapy or cytokine mobilization and hematopoietic progenitor cell transplantation.
  • Continued evidence by morphology and flow cytometry of bone marrow involvement after at least one cycle of salvage chemotherapy.
  • ≥3 cycles of salvage chemotherapy following documentation of lymphoma relapse or disease progression.
  • (In patients with CD20(+) lymphoma) History of severe reactions to rituximab.
  • Positive pregnancy test in female patients.
  • Lactating female patients.
  • Previously received experimental therapy within 4 weeks of enrolling in this protocol or currently enrolled in another experimental protocol during G-CSF Mobilization Phase.
  • Creatinine >1.5 times the .
  • >1.5 times the ULN.
  • \<45%.
  • Diffusion capacity of the lung for carbon monoxide (DLCO) \<50%.
  • Patients of unwilling to implement adequate .
  • A co-morbid condition that renders the patient at high risk from treatment complications.
  • Residual acute medical condition resulting from prior chemotherapy.
  • Documented history of ventricular arrhythmias during the last 3 years.
  • Fever (temperature >38 °C/100.4 °F).
  • Actual body weight exceeds 175% of ideal body weight.
  • Participants who have deterioration of their clinical status or laboratory parameters between the time of enrolment and transplant (such that they no longer meet entry criteria) may be removed from study at the discretion of the treating physician, principal investigator, or sponsor.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    G-CSF plus plerixafor

    Participants with CD20- lymphoma

    Drug: G-CSF plus plerixafor

  • Experimental
    G-CSF plus plerixafor and rituximab

    Participants with CD20+ lymphoma

    Drug: G-CSF plus plerixafor · Biological: rituximab

Interventions

  • DrugG-CSF plus plerixafor

    Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor

    Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

    Also known as: AMD3100, Mozobil

  • DrugG-CSF plus plerixafor

    Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor

    Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5\*10\^6 CD34+ cells/kg were collected.

    Also known as: Mozobil, AMD3100

  • Biologicalrituximab

    Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.

    Also known as: Rituxan, MabThera

06

What researchers measure

Primary outcomes

  1. Summary of Adverse Events (AEs)

    Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization in participants with CD20- lymphoma or start of rituximab in participants with CD20+ lymphoma) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for seriousness and relatedness to study treatment.

    Time frame: Day 1 and up to Day 59 (maximum time before start of chemotherapy)

Secondary outcomes

  1. Median Cumulative Number of CD34+ Cells Collected During Apheresis

    Median total number of CD34+ cells collected during apheresis.

    Time frame: Days 5-8

  2. Median Fold Increase in the Number of CD34+ Cells After Plerixafor Administration

    Fold Increase = (Pre-Apheresis CD34+ cells/Pre-Plerixafor CD34+ cells).

    Time frame: Days 4-5

  3. Median Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg

    Median number of apheresis days in each treatment arm to collect a minimum of 3\*10\^6 CD34+ cells/kg.

    Time frame: Days 5-8

  4. Median Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg

    Median number of apheresis days in each treatment arm to reach the target of 5\*10\^6 CD34+ cells/kg.

    Time frame: Days 5-8

  5. Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment

    Median number of days from transplantation to PMN engraftment which was defined as PMN counts ≥0.5\*10\^9/L for 3 consecutive days or ≥1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.

    Time frame: Days post transplantation (approximately Day 40)

  6. Median Number of Days to Platelet (PLT) Engraftment

    Median number of days from transplantation to PLT engraftment which was defined as platelet counts ≥20\*10\^9/L without transfusion for the preceding 7 days or platelet counts ≥50\*10\^9/L for one day. Time to engraftment corresponded to the first day that the criteria were met.

    Time frame: Days post transplantation (approximately Day 40)

  7. Median Number of Days to Lymphocyte Engraftment

    Median number of days from transplantation to lymphocyte engraftment which was defined as lymphocyte counts ≥5\*10\^8/L. Time to engraftment corresponded to the first day that criteria were met.

    Time frame: Days post transplantation (approximately Day 40)

  8. Median Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant

    Time frame: Approximately 7 months (6 months post-transplant)

  9. Median Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant

    Time frame: 13 months (12 months post-transplant)

  10. The Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day

    Time frame: Day 5

  11. Number of Participants With Durable Engraftment 12 Months After Transplantation

    The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.

    Time frame: Approximately 13 months (12 months post-transplant )

07

Results

Posted Jul 29, 2010

Participant flow

Participant flow — Overall Study
MilestoneG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Started1515
Received plerixafor1515
Received transplant1414
Completed1213
Not completed32
Withdrew: Death12
Withdrew: Lost to follow-up10
Withdrew: Participant failed mobilization10

Outcome measures

PrimarySummary of Adverse Events (AEs)

Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization in participants with CD20- lymphoma or start of rituximab in participants with CD20+ lymphoma) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for seriousness and relatedness to study treatment.

Time frame:
Day 1 and up to Day 59 (maximum time before start of chemotherapy)
Reported as:
Number · participants
Summary of Adverse Events (AEs)
participantsG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Participants Reporting at Least 1 AE913
Participant Count of Mild AEs712
Participant Count of Moderate AEs20
Participant Count of Severe AEs00
Participant Count of Life-Threatening AEs01
AEs by Relationship - Not Related10
AEs by Relationship - Probably Not Related34
AEs by Relationship - Possibly Related05
AEs by Relationship - Probably Related23
AEs by Relationship - Definitely Related31
SecondaryMedian Cumulative Number of CD34+ Cells Collected During Apheresis

Median total number of CD34+ cells collected during apheresis.

Time frame:
Days 5-8
Reported as:
Median · CD34+ cells (*10^6 / kg)
Median Cumulative Number of CD34+ Cells Collected During Apheresis
CD34+ cells (*10^6 / kg)G-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Median Cumulative Number of CD34+ Cells Collected During Apheresis7.4 (0.9 to 14.1)6.4 (2.5 to 10.9)
SecondaryMedian Fold Increase in the Number of CD34+ Cells After Plerixafor Administration

Fold Increase = (Pre-Apheresis CD34+ cells/Pre-Plerixafor CD34+ cells).

Time frame:
Days 4-5
Reported as:
Median · fold increase
Median Fold Increase in the Number of CD34+ Cells After Plerixafor Administration
fold increaseG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Median Fold Increase in the Number of CD34+ Cells After Plerixafor Administration2.4 (1.6 to 1321.3)2.5 (1.6 to 68.5)
SecondaryMedian Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg

Median number of apheresis days in each treatment arm to collect a minimum of 3\*10\^6 CD34+ cells/kg.

Time frame:
Days 5-8
Reported as:
Median · days
Median Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg
daysG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Median Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg1.0 (1.0 to 3.0)1.0 (1.0 to 2.0)
SecondaryMedian Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg

Median number of apheresis days in each treatment arm to reach the target of 5\*10\^6 CD34+ cells/kg.

Time frame:
Days 5-8
Reported as:
Median · days
Median Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg
daysG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Median Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg1.0 (1.0 to 4.0)2.0 (1.0 to 3.0)
SecondaryMedian Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment

Median number of days from transplantation to PMN engraftment which was defined as PMN counts ≥0.5\*10\^9/L for 3 consecutive days or ≥1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.

Time frame:
Days post transplantation (approximately Day 40)
Reported as:
Median · days
Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment
daysG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment13.0 (11.0 to 21.0)13.5 (11.0 to 16.0)
SecondaryMedian Number of Days to Platelet (PLT) Engraftment

Median number of days from transplantation to PLT engraftment which was defined as platelet counts ≥20\*10\^9/L without transfusion for the preceding 7 days or platelet counts ≥50\*10\^9/L for one day. Time to engraftment corresponded to the first day that the criteria were met.

Time frame:
Days post transplantation (approximately Day 40)
Reported as:
Median · days
Median Number of Days to Platelet (PLT) Engraftment
daysG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Median Number of Days to Platelet (PLT) Engraftment21.0 (13.0 to 31.0)22.0 (16.0 to 28.0)
SecondaryMedian Number of Days to Lymphocyte Engraftment

Median number of days from transplantation to lymphocyte engraftment which was defined as lymphocyte counts ≥5\*10\^8/L. Time to engraftment corresponded to the first day that criteria were met.

Time frame:
Days post transplantation (approximately Day 40)
Reported as:
Median · days
Median Number of Days to Lymphocyte Engraftment
daysG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Median Number of Days to Lymphocyte Engraftment14.5 (9.0 to 32.0)14.0 (7.0 to 22.0)
SecondaryMedian Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant
Time frame:
Approximately 7 months (6 months post-transplant)
Reported as:
Median · cells / μL
Median Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant
cells / μLG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Median Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant155.00 (61.00 to 311.00)0.50 (0.00 to 4.00)
SecondaryMedian Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant
Time frame:
13 months (12 months post-transplant)
Reported as:
Median · cells / μL
Median Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant
cells / μLG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Median Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant322.50 (189.00 to 518.00)236.00 (0.00 to 457.00)
SecondaryThe Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day
Time frame:
Day 5
Reported as:
Median · percentage of total cells
The Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day
percentage of total cellsG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
The Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day2.83 (0.07 to 7.86)0.09 (0.01 to 0.39)
SecondaryNumber of Participants With Durable Engraftment 12 Months After Transplantation

The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.

Time frame:
Approximately 13 months (12 months post-transplant )
Reported as:
Number · participants
Number of Participants With Durable Engraftment 12 Months After Transplantation
participantsG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
Number of Participants With Durable Engraftment 12 Months After Transplantation1213

Adverse events

Collected over First day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for the first transplant. This timeframe includes G-CSF and plerixafor administration (rituximab if applicable), and the rest period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
G-CSF and Plerixafor—0/15 (0%)9/15 (60%)
G-CSF and Plerixafor + Rituximab—1/15 (6.7%)13/15 (86.7%)
Most frequent serious events
Most frequent serious events
EventG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
CholelithiasisHepatobiliary disorders0/151/15
LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/151/15
Most frequent other events
Showing 10 of 53
Most frequent other events
EventG-CSF and PlerixaforG-CSF and Plerixafor + Rituximab
NauseaGastrointestinal disorders1/154/15
Injection site erythemaGeneral disorders3/151/15
PyrexiaGeneral disorders1/153/15
DiarrhoeaGastrointestinal disorders1/152/15
Paraesthesia oralGastrointestinal disorders2/152/15
VomitingGastrointestinal disorders0/152/15
Catheter site painGeneral disorders2/150/15
HypokalaemiaMetabolism and nutrition disorders0/152/15
Bone painMusculoskeletal and connective tissue disorders1/152/15
Hot flushVascular disorders0/152/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)G-CSF and PlerixaforG-CSF and Plerixafor + RituximabTotal
Mean39.3 ± 11.346.5 ± 14.942.9 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)G-CSF and PlerixaforG-CSF and Plerixafor + RituximabTotal
Female639
Male91221
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)G-CSF and PlerixaforG-CSF and Plerixafor + RituximabTotal
Caucasian121022
African-American314
Asian000
Hispanic/Latino022
Other022
Disease Diagnosis
Disease Diagnosis(Participants)G-CSF and PlerixaforG-CSF and Plerixafor + RituximabTotal
Hodgkin disease (HD)14418
Non-Hodgkin lymphoma (NHL)11112
08

Study locations

1 site
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2007
First posted
Mar 8, 2007
Start
Feb 2006
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Jul 29, 2010
Last update
Mar 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00444912
Responsible party
Sponsor
First posted
Mar 8, 2007
Start date
Feb 2006
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Jul 29, 2010
Last update
Mar 13, 2014

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor

Start the discussion